Listen Now

Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D., explain why Mayo Clinic Laboratories' gene panel is the most comprehensive test available for inherited Parkinson's disease. The new panel covers all mutations known to cause the condition — or increase the risk of developing it. (01:37) Can you give us a brief overview of the inherited Parkinson's disease gene panel, and when it would be used, Dr. Niu?   (02:31) Dr. Savica, can you give us a brief overview of the inherited Parkinson's disease gene panel, and when it would be used?   (03:34) What unique features set this test apart from the market, Dr. Niu?   (04:07) Dr. Savica, what features do you see that set this test apart in the market?   (05:19) Who would benefit from this test, and when should it be performed?   (06:46) Can you summarize the benefits of doing the inherited Parkinson's disease gene panel at Mayo, Dr. Niu?   (07:36) Dr. Savica, can you summarize the benefits of doing the inherited Parkinson's disease gene panel at Mayo?

(00:31) Dr. Niu, could you provide us with a little bit of your background? (01:03) Dr. Klein, could you provide us with a little bit of your background?   (01:40) Would you give us a brief overview of the new panel?   (02:49) Dr. Klein, could you give us a simple background of what you see going on in this space?   (03:33) Which patients should have this testing, and when should it be performed? (04:49) Are there alternatives available, and how do they compare with this new MUPAN panel?   (05:51) How are the results used in patient care?   (07:24) How does this new test affect patient care?

Many laboratorians are not patient-facing. So, while laboratories are critical to patient care, they may lack visibility when it comes to policymaking.  In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, discuss their leadership roles in national advocacy organizations and the importance of laboratorian engagement in the federal regulatory process.

(00:31) Would each of you share a little bit about yourselves and your backgrounds?  (01:47) Could you provide us with an overview of what the WGSDX test is?   (02:26) How is that different from other genetic tests, like exome or microarray?   (03:56) Tell us more about who benefits from these tests.   (07:17) Is this test recommended by expert groups?   (09:10) How do providers go about ordering this test, and what sample types are accepted?   (11:12) What type of variants are detected by this test?   (13:04) How would you say our test matches up to other genome tests available on the market?   (14:04) What about medically actionable secondary findings?   (14:55) Are there any other unique features?   (16:07) Could you summarize the benefits of doing WGSDX at Mayo?

(00:31) Could you provide a little bit about yourself and your background?   (02:04) Could you provide an overview of the chromosomal microarray assay?   (05:49) Why should the chromosomal microarray assay be used over other available assays, such as FISH?   (08:56) Does the chromosomal microarray provide good benefits in terms of gain of 7 and loss of 10, and EGFR amplification?   (12:03) What's the value of utilizing the test alongside a neuro-specific NGS panel, such as Mayo Clinic Laboratories' NONCP panel?   (17:20) How are the results used in patient care?   (19:41) Is there anything else you feel it's important to highlight?

Norovirus is the No. 1 cause of foodborne illness in the United States. And while most people who contract norovirus recover on their own without the need for testing or treatment, others do not.  In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, discuss what’s behind recent outbreaks of norovirus and how to keep yourself healthy and protected throughout the remainder of this year’s peak norovirus season. 

(00:31): Before we get started, can you tell us a little bit about yourselves and your backgrounds? (02:35):Can you guys give us a brief overview of this assay and what will be changing to characterize marijuana use? (04:28):So which patients should have this testing and when would you say it should be performed, Dr. Langman? (05:58):Are there other test options available and if, and if so, how do these compare? (07:03):This is really the best way to accurately characterize marijuana use. Would you say that's true? (07:11):And then could you, Dr. Langman, explain how the results are used in patient care?

William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories , joins “Answers From the Lab” for his weekly leadership update with host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Dr. Morice and Dr. Pritt discuss laboratory medicine from an international perspective: what advances are being made, how we educate future practitioners, and the need for global collaboration.

(00:32) Can you tell our audience a little bit about yourself and your role here at Mayo Clinic? (01:29) Can you tell our listeners a little bit about the disease state when we talk about autoimmune or paraneoplastic movement disorders? (02:37) Are we seeing an increased prevalence of autoimmune movement disorders? (04:00) Can you give our listeners an overview of what's going to be launched here in January? (06:56) What other antibodies are particularly important in this phenotype? (10:01) How does the kelch-like protein 11 phenotype manifest in this disorder? (10:49) Are there any antibodies in the autoimmune neurology space that would not need to be evaluated for in patients that present with some sort of movement disorder?  (11:18) Which patients should have this testing and when should it be performed? (12:55) When should Mayo Clinic Laboratories' stiff person evaluation and standalone glycine receptor tests be used, and in what order? (14:40) Is the movement disorder evaluation the right first choice when the patient presentation is less typical and includes ataxia? (16:42) Can physicians order the glycine receptor standalone test to fully evaluate the spectrum of antibodies? (18:39) How does the evaluation impact patient care? (20:12) Have these new antibodies been shown to be immunotherapy-responsive? (20:27) Is there a key takeaway with the launch of these new antibodies in the movement disorder evaluation?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, sits down with Joaquin Garcia, M.D., chair of Mayo Clinic’s Division of Anatomic Pathology and digital pathology program to discuss how the advent of digital pathology is changing patient care at Mayo Clinic.

(00:31) Could you provide our listeners with a little bit about yourself and your background? (01:48) Could you give an overview of the new neuro-oncology expanded gene panel by next generation sequencing?   (03:43) Can you describe a little bit more about some examples of genes that were in the 2021 WHO classification that are now included in the NONCP panel?   (06:50) Does this panel have high clinical utility in both in adult and pediatric cases?   (08:05) Is picking up on copy numbers useful in both adult and pediatric cases?   (09:12) Could you discuss a little bit more about how these results would be used in patient care?   (10:27) Do you have anything else you would like to add about the enhanced neuro-oncology NGS panel?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., and William Morice II, M.D., Ph.D., provide an update on this year’s triple-demic of respiratory viruses, discuss the future of at-home testing, and preview future pandemic preparedness efforts.

William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, joins “Answers From the Lab” for his weekly leadership update with host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Dr. Morice shares his biggest takeaways from this year’s J.P. Morgan Healthcare Conference in San Francisco, California, and gives an update on the COVID-19 public health emergency.

(00:32) Could you provide us with a little bit of your background? (01:12) Could you give us an overview of this test and a summary of the assay? (01:40) What kind of patients should expect to have this test ordered? (04:11) Are other tests available that identify EDN activation in patients? (05:11) How do you envision physicians using this test to treat patients? (06:32) Can you expand on how the test is used in patient treatment?

William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, joins Bobbi Pritt, M.D., on this week’s episode of the "Answers From the Lab" podcast. In this episode, they kick off the new year with a legislative update and discuss at-home testing options in the wake of the new subvariant of COVID-19.

Steven Ansell, M.D., Ph.D., chair of the Division of Hematology and senior deputy director, Midwest, Mayo Clinic Comprehensive Cancer Center, joins the "Answers From the Lab" podcast for a discussion with host Bobbi Pritt, M.D., about declining cancer death rates. In this episode, Dr. Ansell and Dr. Pritt discuss advancements in cancer treatments that are leading to declining death rates, the role diagnostics plays in cancer treatment, and what the future may hold for cancer diagnostics.

Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory at Mayo Clinic, joins host Bobbi Pritt, M.D., on this week’s episode of the "Answers From the Lab" podcast. In this episode, they discuss the ongoing respiratory virus season, a new test for measles available at Mayo Clinic Laboratories, and some tips to stay healthy.

William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, joins “Answers From the Lab” for his weekly leadership update with host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Drs. Pritt and Morice share their predictions for the new year and discuss why they believe 2023 will be a pivotal year for health care.

William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, joins “Answers From the Lab” for his weekly leadership update with host Bobbi Pritt, M.D., interim chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Drs. Pritt and Morice discuss how offering specialty testing for conditions like Stiff-Person Syndrome and Alpha-Gal helps to advance innovation and give patients the answers they need.